We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorMuhe, Janine
dc.contributor.authorAye, Pyone Pyone
dc.contributor.authorQuink, Carol
dc.contributor.authorEng, Jing Ying
dc.contributor.authorEngelman, Kathleen D.
dc.contributor.authorReimann, Keith A.
dc.contributor.authorWang, Fred
dc.date2022-08-11T08:10:01.000
dc.date.accessioned2022-08-23T16:52:17Z
dc.date.available2022-08-23T16:52:17Z
dc.date.issued2021-07-20
dc.date.submitted2022-01-02
dc.identifier.citation<p>Mühe J, Aye PP, Quink C, Eng JY, Engelman K, Reimann KA, Wang F. Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model. Cell Rep Med. 2021 Jul 21;2(7):100352. doi: 10.1016/j.xcrm.2021.100352. PMID: 34337567; PMCID: PMC8324488. <a href="https://doi.org/10.1016/j.xcrm.2021.100352">Link to article on publisher's site</a></p>
dc.identifier.issn2666-3791 (Linking)
dc.identifier.doi10.1016/j.xcrm.2021.100352
dc.identifier.pmid34337567
dc.identifier.urihttp://hdl.handle.net/20.500.14038/42024
dc.description.abstractEpstein-Barr virus (EBV) and related lymphocryptoviruses (LCVs) from nonhuman primates are transmitted through oral secretions, penetrate the mucosal epithelium, and establish persistent infection in B cells. To determine whether neutralizing antibodies against epithelial or B cell infection could block oral transmission and persistent LCV infection, we use rhesus macaques, the most accurate animal model for EBV infection by faithfully reproducing acute and persistent infection in humans. Naive animals are infused with monoclonal antibodies neutralizing epithelial cell infection or B cell infection and then challenged orally with recombinant rhesus LCV. Our data show that high-titer B cell-neutralizing antibodies alone, but not epithelial cell-neutralizing antibodies, can provide complete protection of rhesus macaques from oral LCV challenge, but not in all hosts. Thus, neutralizing antibodies against B cell infection are important targets for EBV vaccine development, but they may not be sufficient.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34337567&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject72A1
dc.subjectE1D1
dc.subjectEBV vaccine
dc.subjectEpstein-Barr virus
dc.subjectlymphocryptovirus
dc.subjectImmunology and Infectious Disease
dc.subjectVirus Diseases
dc.subjectViruses
dc.titleNeutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model
dc.typeJournal Article
dc.source.journaltitleCell reports. Medicine
dc.source.volume2
dc.source.issue7
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5860&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4827
dc.identifier.contextkey27074138
refterms.dateFOA2022-08-23T16:52:17Z
html.description.abstract<p>Epstein-Barr virus (EBV) and related lymphocryptoviruses (LCVs) from nonhuman primates are transmitted through oral secretions, penetrate the mucosal epithelium, and establish persistent infection in B cells. To determine whether neutralizing antibodies against epithelial or B cell infection could block oral transmission and persistent LCV infection, we use rhesus macaques, the most accurate animal model for EBV infection by faithfully reproducing acute and persistent infection in humans. Naive animals are infused with monoclonal antibodies neutralizing epithelial cell infection or B cell infection and then challenged orally with recombinant rhesus LCV. Our data show that high-titer B cell-neutralizing antibodies alone, but not epithelial cell-neutralizing antibodies, can provide complete protection of rhesus macaques from oral LCV challenge, but not in all hosts. Thus, neutralizing antibodies against B cell infection are important targets for EBV vaccine development, but they may not be sufficient.</p>
dc.identifier.submissionpathoapubs/4827
dc.contributor.departmentMassBiologics
dc.source.pages100352


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
1_s2.0_S2666379121002019_main.pdf
Size:
1.239Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as Copyright © 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).